Clinical Trial Update: A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describing AK104 or AK112 in combination with Axitinib for metastatic mucosal melanoma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Mucosal Melanoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK112
• Axitinib (Axitinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma, Mucosal Melanoma | Phase 1 | Status: NOT_YET_RECRUITING